Xlife Sciences AG: Exit of a project company

More than 20 million euros transaction completed

MUNICH–(BUSINESS WIRE)–Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.

Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the technological development of Araxa has been successfully advanced.

About Veraxa Biotech AG

Veraxa Biotech AG identifies and develops functional antibodies and antibody drug conjugates (ADC’s) for the bio- and pharmaceutical industry in exchange for license agreements. The aim is to accelerate the safe development of medical drugs, as well as to enhance the probabilities of drug developments in various clinical phases. Using this technology, Veraxa Biotech AG can screen millions of b-cells in one single step in less than 48 hours for functional antibodies and additionally also modify them with drug conjugates.

About Xlife Sciences AG

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. (Read more…) Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

Contacts

For media inquiries:
Oliver R. Baumann

CEO Xlife Sciences AG

Tel. +41 44 385 84 60

[email protected]